Review article: The diagnosis and management of alcoholic hepatitis

Alimentary Pharmacology and Therapeutics

Volumn 30, Issue 1, 2009, Pages 3-13

  Cohen, S M ^a   Ahn, J ^a  

^a RUSH UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLCYSTEINE; ALANINE AMINOTRANSFERASE; ANTIOXIDANT; ASPARTATE AMINOTRANSFERASE; BACLOFEN; COLCHICINE; CORTICOSTEROID; ETANERCEPT; FOLIC ACID; GLUCAGON; INFLIXIMAB; INSULIN; MULTIVITAMIN; NALTREXONE; OXANDROLONE; PENTOXIFYLLINE; PLACEBO; PREDNISOLONE; PROPYLTHIOURACIL; SILYBUM MARIANUM EXTRACT; TESTOSTERONE; TUMOR NECROSIS FACTOR INHIBITOR; UBIQUINONE; VITAMIN B GROUP; VITAMIN K GROUP; ZINC;

ADD ON THERAPY; ALCOHOL ABSTINENCE; ALCOHOL ABUSE; ALCOHOL CONSUMPTION; ALCOHOL LIVER DISEASE; ALCOHOLISM; CALORIC INTAKE; CLINICAL EXAMINATION; CLINICAL FEATURE; CLINICAL TRIAL; CORTICOSTEROID THERAPY; DIET THERAPY; DIFFERENTIAL DIAGNOSIS; DISEASE SEVERITY; DRUG CONTRAINDICATION; DRUG EFFICACY; DRUG FATALITY; DRUG INDICATION; DRUG MECHANISM; DRUG MEGADOSE; DRUG SUBSTITUTION; DRUG WITHDRAWAL; HUMAN; LABORATORY TEST; LIVER BIOPSY; LIVER TRANSPLANTATION; MORTALITY; NONHUMAN; NUTRITIONAL ASSESSMENT; NUTRITIONAL SUPPORT; PATIENT COUNSELING; PRIORITY JOURNAL; REVIEW; SURVIVAL RATE; TREATMENT DURATION; TREATMENT OUTCOME; VITAMIN SUPPLEMENTATION;

ANABOLIC AGENTS; ANTI-INFLAMMATORY AGENTS; ANTIOXIDANTS; HEPATITIS, ALCOHOLIC; HUMANS; LIVER TRANSPLANTATION; NUTRITIONAL SUPPORT; PENTOXIFYLLINE; PHOSPHODIESTERASE INHIBITORS; PREDNISOLONE; SEVERITY OF ILLNESS INDEX; TEMPERANCE; TUMOR NECROSIS FACTOR-ALPHA;

EID: 67449088475     PISSN: 02692813     EISSN: 13652036     Source Type: Journal    
DOI: 10.1111/j.1365-2036.2009.04002.x     Document Type: Review

References (116)

1. Maddrey WC, Boitnott JK, Bedine MS, Weber FL Jr., Mezey E, White RI Jr. Corticosteroid therapy of alcoholic hepatitis. Gastroenterology 1978 75 : 193 9.
2. Carithers RL Jr., Herlong HF, Diehl AM, et al. Methylprednisolone therapy in patients with severe alcoholic hepatitis. A randomized multicenter trial. Ann Intern Med 1989 110 : 685 90.
3. Mendenhall CL, Moritz TE, Roselle GA, et al. A study of oral nutritional support with oxandrolone in malnourished patients with alcoholic hepatitis: results of a Department of Veterans Affairs cooperative study. Hepatology 1993 17 : 564 76.
4. Phillips M, Curtis H, Portmann B, Donaldson N, Bomford A, O'Grady J. Antioxidants versus corticosteroids in the treatment of severe alcoholic hepatitis - a randomised clinical trial. J Hepatol 2006 44 : 784 90.
5. Stewart S, Prince M, Bassendine M, et al. A randomized trial of antioxidant therapy alone or with corticosteroids in acute alcoholic hepatitis. J Hepatol 2007 47 : 277 83.
6. Bellentani S, Saccoccio G, Costa G, et al. Drinking habits as cofactors of risk for alcohol induced liver damage. The Dionysos Study Group. Gut 1997 41 : 845 50.
7. Mandayam S, Jamal MM, Morgan TR. Epidemiology of alcoholic liver disease. Semin Liver Dis 2004 24 : 217 32.
8. Wilfred de Alwis NM, Day CP. Genetics of alcoholic liver disease and nonalcoholic fatty liver disease. Semin Liver Dis 2007 27 : 44 54. (Pubitemid 46269804)
9. Tao N, Sussman S, Nieto J, Tsukamoto H, Yuan JM. Demographic characteristics of hospitalized patients with alcoholic liver disease and pancreatitis in Los Angeles county. Alcohol Clin Exp Res 2003 27 : 1798 804.
10. Naveau S, Giraud V, Borotto E, Aubert A, Capron F, Chaput JC. Excess weight risk factor for alcoholic liver disease. Hepatology 1997 25 : 108 11.
11. Becker U, Deis A, Sorensen TI, et al. Prediction of risk of liver disease by alcohol intake, sex, and age: a prospective population study. Hepatology 1996 23 : 1025 9.
12. Orrego H, Blake JE, Blendis LM, Kapur BM, Israel Y. Reliability of assessment of alcohol intake based on personal interviews in a liver clinic. Lancet 1979 2 : 1354 6.
13. Han SH, Rice S, Cohen SM, Reynolds TB, Fong TL. Duplex Doppler ultrasound of the hepatic artery in patients with acute alcoholic hepatitis. J Clin Gastroenterol 2002 34 : 573 7.
14. Cohen JA, Kaplan MM. The SGOT/SGPT ratio - an indicator of alcoholic liver disease. Dig Dis Sci 1979 24 : 835 8.
15. Sorbi D, Boynton J, Lindor KD. The ratio of aspartate aminotransferase to alanine aminotransferase: potential value in differentiating nonalcoholic steatohepatitis from alcoholic liver disease. Am J Gastroenterol 1999 94 : 1018 22.
16. Jamal MM, Morgan TR. Liver disease in alcohol and hepatitis C. Best Pract Res Clin Gastroenterol 2003 17 : 649 62.
17. Mendenhall CL, Moritz T, Chedid A, et al. Relevance of anti-HCV reactivity in patients with alcoholic hepatitis. VA cooperative Study Group #275. Gastroenterol Jpn 1993 28 : 95 100.
18. Verma S, Ajudia K, Mendler M, Redeker A. Prevalence of septic events, type 1 hepatorenal syndrome, and mortality in severe alcoholic hepatitis and utility of discriminant function and MELD score in predicting these adverse events. Dig Dis Sci 2006 51 : 1637 43.
19. Sumino Y, Kravetz D, Kanel GC, McHutchison JG, Reynolds TB. Ultrasonographic diagnosis of acute alcoholic hepatitis 'pseudoparallel channel sign' of intrahepatic artery dilatation. Gastroenterology 1993 105 : 1477 82.
20. Levin DM, Baker AL, Riddell RH, Rochman H, Boyer JL. Nonalcoholic liver disease. Overlooked causes of liver injury in patients with heavy alcohol consumption. Am J Med 1979 66 : 429 34.
21. Mathurin P, Poynard T, Ramond MJ, et al. Interet de la biopsie hepatique pour la selection des sujets suspects d'hepatitis alcoolique aigue. Journees francophones d'hepatologie et de pathologies digestives. Gastroenterol Clin Biol 1992 16 : 231A.
22. Lebrec D, Goldfarb G, Degott C, Rueff B, Benhamou JP. Transvenous liver biopsy: an experience based on 1000 hepatic tisuue samplings with the procedure. Gastroenterology 1982 83 : 338 40.
23. Bull HJ, Gilmore IT, Bradley RD, Marigold JH, Thompson RP. Experience with transjugular liver biopsy. Gut 1983 24 : 1057 60.
24. Rockey DC, Caldwell SH, Goodman ZD, Nelson RC, Smith AD. Liver biopsy. Hepatology 2009 49 : 1017 44.
25. Chedid A, Mendenhall CL, Moritz TE, et al. Cell-mediated hepatic injury in alcoholic liver disease. Veterans Affairs Cooperative Study Group 275. Gastroenterology 1993 105 : 254 66.
26. Lefkowitch JH. Morphology of alcoholic liver disease. Clin Liv Dis 2005 9 : 37 53. (Pubitemid 40341945)
27. French SW, Nash J, Shitabata P, et al. Pathology of alcoholic liver disease. VA Cooperative Study Group 119. Semin Liv Dis 1993 13 : 154 69.
28. Spahr L, Rubbia-Brandt L, Pugin J, et al. Rapid changes in alcoholic hepatitis histology under steroids: correlation with soluble intercellular adhesion molecule-1 in hepatic venous blood. J Hepatol 2001 35 : 582 9.
29. Wells JT, Said A, Agni R, et al. The impact of acute alcoholic hepatitis in the explanted recipient liver on outcome after liver transplantation. Liver Transpl 2007 13 : 1728 35.
30. Tripodi A, Caldwell SH, Hoffman M, Trotter JF, Sanyal AJ. Review article: the prothrombin time test as a measure of bleeding risk and prognosis in liver disease. Aliment Pharmacol Ther 2007 26 : 141 8.
31. Kamath PS, Wiesner RH, Malinchoc M, et al. A model to predict survival in patients with end-stage liver disease. Hepatology 2001 33 : 464 70.
32. Kamath PS, Kim WR, Advanced Liver Disease Study Group. The model for end-stage liver disease (MELD). Hepatology 2007 45 : 797 805. (Pubitemid 46450631)
33. Dunn W, Jamil LH, Brown LS, et al. MELD accurately predicts mortality in patients with alcoholic hepatitis. Hepatology 2005 41 : 353 8.
34. Srikureja W, Kyulo NL, Runyon BA, Hu KQ. MELD score is a better prognostic model than Child-Turcotte-Pugh score or Discriminant Function score in patients with alcoholic hepatitis. J Hepatol 2005 42 : 700 6.
35. International Committee for Standardization in Haematology, International Committee on Thrombosis and Haemostasis: ICSH/ICTH recommendations for reporting prothrombin time in oral anticoagulant control. Thromb Haemost 1985 53 : 155 6.
36. Caldwell S, Shah N. The prothrombin time-derived international normalized ratio: great for Warfarin, fair for prognosis and bad for liver-bleeding risk. Liver Int 2008 28 : 1325 7.
37. Tripodi A, Chantarangkul V, Mannucci PM. The international normalized ratio to prioritize patients for liver transplantation: problems and possible solutions. J Thromb Haemost 2008 6 : 243 8.
38. Forrest EH, Evans CD, Stewart S, et al. Analysis of factors predictive of mortality in alcoholic hepatitis and derivation and validation of the Glasgow alcoholic hepatitis score. Gut 2005 54 : 1174 9.
39. Forrest EH, Morris AJ, Stewart S, et al. The Glasgow alcoholic hepatitis score identifies patients who may benefit from corticosteroids. Gut 2007 56 : 1743 6.
40. Alexander JF, Lischner MW, Galambos JT. Natural history of alcoholic hepatitis. II. The long-term prognosis. Am J Gastroenterol 1971 56 : 515 25.
41. Powell WJ Jr., Klatskin G. Duration of survival in patients with Laennec's cirrhosis. Influence of alcohol withdrawal, and possible effects of recent changes in general management of the disease. Am J Med 1968 44 : 406 20.
42. Anton RF, O'Malley SS, Ciraulo DA, et al. Combined pharmacotherapies and behavioral interventions for alcohol dependence: the COMBINE study: a randomized controlled trial. JAMA 2006 295 : 2003 17.
43. Mason BJ, Goodman AM, Chabac S, Lehert P. Effect of oral acamprosate on abstinence in patients with alcohol dependence in a double-blind, placebo-controlled trial: the role of patient motivation. J Psychiatr Res 2006 40 : 383 93.
44. Chick J, Lehert P, Landron F, Plinius Maior Society. Does acamprosate improve reduction of drinking as well as aiding abstinence? J Psychopharmacol 2003 17 : 397 402. (Pubitemid 38076334)
45. Mason BJ. Acamprosate. Recent Dev Alcohol 2003 16 : 203 15.
46. Addolorato G, Caputo F, Capristo E, et al. Baclofen efficacy in reducing alcohol craving and intake: a preliminary double-blind randomized controlled study. Alcohol Alcohol 2002 37 : 504 8.
47. Flannery BA, Garbutt JC, Cody MW, et al. Baclofen for alcohol dependence: a preliminary open-label study. Alcohol Clin Exp Res 2004 28 : 1517 23.
48. Addolorato G, Leggio L, Ferrulli A, et al. Effectiveness and safety of baclofen for maintenance of alcohol abstinence in alcohol-dependent patients with liver cirrhosis: randomised, double-blind controlled study. Lancet 2007 370 : 1915 22.
49. Niemela O, Risteli J, Blake JE, Risteli L, Compton KV, Orrego H. Markers of fibrogenesis and basement membrane formation in alcoholic liver disease. Relation to severity, presence of hepatitis, and alcohol intake. Gastroenterology 1990 98 : 1612 9.
50. Reynolds TB, Geller HM, Kuzma OT, Redeker AG. Spontaneous decrease in portal pressure with clinical improvement in cirrhosis. N Engl J Med 1960 263 : 734 9.
51. Mendenhall CL, Anderson S, Weesner RE, Goldberg SJ, Crolic KA. Protein-calorie malnutrition associated with alcoholic hepatitis. Veterans Administration Cooperative Study Group on Alcoholic Hepatitis. Am J Med 1984 76 : 211 22.
52. Mendenhall CL, Tosch T, Weesner RE, et al. VA cooperative study on alcoholic hepatitis. II: Prognostic significance of protein-calorie malnutrition. Am J Clin Nutr 1986 43 : 213 8.
53. DiCecco SR, Francisco-Ziller N. Nutrition in alcoholic liver disease. Nutr Clin Pract 2006 21 : 245 54.
54. Halsted CH. Nutrition and alcoholic liver disease. Semin Liver Dis 2004 24 : 289 304. (Pubitemid 39167686)
55. Nielsen K, Kondrup J, Martinsen L, Stilling B, Wikman B. Nutritional assessment and adequacy of dietary intake in hospitalized patients with alcoholic liver cirrhosis. Br J Nutr 1993 69 : 665 79.
56. Bode JC, Hanisch P, Henning H, Koenig W, Richter FW, Bode C. Hepatic zinc content in patients with various stages of alcoholic liver disease and in patients with chronic active and chronic persistent hepatitis. Hepatology 1988 8 : 1605 9.
57. Kiilerich S, Dietrichson O, Loud FB, et al. Zinc depletion in alcoholic liver diseases. Scand J Gastroenterol 1980 15 : 363 7.
58. Kang YJ, Zhou Z. Zinc prevention and treatment of alcoholic liver disease. Mol Aspects Med 2005 26 : 391 404. (Pubitemid 41225361)
59. Henkel AS, Buchman AL. Nutritional support in patients with chronic liver disease. Nat Clin Pract Gastroenterol Hepatol 2006 3 : 202 9.
60. Stickel F, Hoehn B, Schuppan D, Seitz HK. Review article: nutritional therapy in alcoholic liver disease. Aliment Pharmacol Ther 2003 18 : 357 73.
61. Cabre E, Rodriguez-Iglesias P, Caballeria J, et al. Short- and long-term outcome of severe alcohol-induced hepatitis treated with steroids or enteral nutrition: a multicenter randomized trial. Hepatology 2000 32 : 36 42. (Pubitemid 30432363)
62. Plauth M, Cabre E, Riggio O, et al. ESPEN Guidelines on enteral nutrition: liver disease. Clin Nutr 2006 25 : 285 94.
63. Morgan TR, Moritz TE, Mendenhall CL, Haas R. Protein consumption and hepatic encephalopathy in alcoholic hepatitis. VA Cooperative Study Group #275. J Am Coll Nutr 1995 14 : 152 8.
64. Schulz GJ, Campos AC, Coelho JC. The role of nutrition in hepatic encephalopathy. Curr Opin Clin Nutr Metab Care 2008 11 : 275 80.
65. McCullough AJ, O'Connor JF. Alcoholic liver disease: proposed recommendations for the American College of Gastroenterology. Am J Gastroenterol 1998 93 : 2022 36.
66. Christensen E, Gluud C. Glucocorticoids are ineffective in alcoholic hepatitis: a meta-analysis adjusting for confounding variables. Gut 1995 37 : 113 8.
67. Daures JP, Peray P, Bories P, et al. [Corticoid therapy in the treatment of acute alcoholic hepatitis. Results of a meta-analysis]. Gastroenterol Clin Biol 1991 15 : 223 8.
68. Imperiale TF, McCullough AJ. Do corticosteroids reduce mortality from alcoholic hepatitis? A meta-analysis of the randomized trials Ann Intern Med 1990 113 : 299 307. (Pubitemid 20254358)
69. Reynolds TB, Benhamou J, Blake JE, Naccarato R, Orrego H. Treatment of alcoholic hepatitis. Gastroenterol Int 1989 2 : 208 16.
70. Helman RA, Temko MH, NYE SW, Fallon HJ. Alcoholic hepatitis: natural history and evaluation of prednisolone therapy. Ann Intern Med 1971 74 : 311 21.
71. Porter HP, Simon FR, Pope CE II., Volwiler W, Fenster LF. Corticosteroid therapy in severe alcoholic hepatitis: a double-blind drug trial. N Eng J Med 1971 284 : 1350 5.
72. Campra JL, Hamlin EM Jr., Kirshbaum RJ, Olivier M, Redeker AG, Reynolds TB. Prednisone therapy of acute alcoholic hepatitis: report of a controlled trial. Ann Intern Med 1973 79 : 625 31.
73. Blitzer BL, Mutchnick MG, Joshi PH, Phillips MM, Fessel JM, Conn HO. Adrenocorticosteroid therapy in alcoholic hepatitis. A prospective double-blind randomized trial. Am J Dig Dis 1977 22 : 477 84.
74. Mendenhall CL, Goldberg S. Risk factors and therapy in alcoholic hepatitis (AH). Gastroenterology 1977 72 : 1100.
75. Lesesne HR, Bozymski EM, Fallon HJ. Treatment of alcoholic hepatitis with encephalopathy. Comparison of prednisolone with caloric supplements. Gastroenterology 1978 74 : 169 73.
76. Galambos JT. Unpublished trial. Quoted by Conn HO. Steroid treatment of alcoholic hepatitis. The yeas and the nays. Gastroenterology 1978 74 : 319 22.
77. Shumaker JB, Resnick RH, Galambos JT, et al. A controlled trial of 6-methylprednisolone in acute alcoholic hepatitis. With a note on published results in encephalopathic patients. Am J Gastroenterol 1978 69 : 443 9.
78. Depew W, Boyer T, Omata M, et al. Double-blind controlled trial of prednisolone therapy in patients with severe acute alcoholic hepatitis and spontaneous encephalopathy. Gastroenterology 1980 78 : 524 9.
79. Theodossi A, Eddleston AL, Williams R. Controlled trial of methylprednisolone therapy in severe acute alcoholic hepatitis. Gut 1982 23 : 75 9.
80. Mendenhall CL, Anderson S, Garcia-Pont P, et al. Short-term and long-term survival in patients with alcoholic hepatitis treated with oxandrolone and prednisolone. N Engl J Med 1984 311 : 1464 70.
81. Bories P, Guedj JY, Mirouze D, et al. Prednisolone treatment of alcoholic hepatitis: forty-five cases. Presse Med 1987 16 : 769 72.
82. Ramond MJ, Poynard T, Rueff B, et al. A randomized trial of prednisolone in patients with severe alcoholic hepatitis. N Engl J Med 1992 326 : 507 12.
83. Richardet JP, Dehoux M, Mal F, et al. Influence of corticosteroids (CS) on plasma cytokines concentrations in patients with severe alcoholic hepatitis (AH): results of a randomized study. J Hepatol 1993 18 : S75.
84. Rambaldi A, Saconato HH, Christensen E, Thorlund K, Wetterslev J, Gluud C. Systematic review: glucocorticosteroids for alcoholic hepatitis - a Cochrane Hepato-Biliary Group systematic review with meta-analyses and trial sequential analyses of randomized clinical trials. Aliment Pharmacol Ther 2008 27 : 1167 78.
85. Mathurin P, Mendenhall CL, Carithers RL Jr., et al. Corticosteroids improve short-term survival in patients with severe alcoholic hepatitis (AH): individual data analysis of the last three randomized placebo controlled double blind trials of corticosteroids in severe AH. J Hepatol 2002 36 : 480 7.
86. Mathurin P, O'Grady J, Carithers RL Jr., et al. Corticosteroids improve 28-day survival in patients with severe alcoholic hepatitis: individual data analysis of the last 5 randomized controlled trials Abstract Hepatology 2008 48 (Suppl.1 635A.
87. Mathurin P, Abdelnour M, Ramond MJ, et al. Early change in bilirubin levels is an important prognostic factor in severe alcoholic hepatitis treated with prednisolone. Hepatology 2003 38 : 1363 9.
88. Louvet A, Naveau S, Abdelnour M, et al. The Lille model: a new tool for therapeutic strategy in patients with severe alcoholic hepatitis treated with steroids. Hepatology 2007 45 : 1348 54.
89. Louvet A, Diaz E, Dharancy S, et al. Early switch to pentoxifylline in patients with severe alcoholic hepatitis is inefficient in non-responders to corticosteroids. J Hepatol 2008 48 : 465 70.
90. Strieter RM, Remick DG, Ward PA, et al. Cellular and molecular regulation of tumor necrosis factor-alpha production by pentoxifylline. Biochem Biophys Res Commun 1988 155 : 1230 6.
91. Akriviadis E, Botla R, Briggs W, Han S, Reynolds T, Shakil O. Pentoxifylline improves short-term survival in severe acute alcoholic hepatitis: a double-blind, placebo-controlled trial. Gastroenterology 2000 119 : 1637 48.
92. Sidhu S, Singla M, Bhatia K. Pentoxfylline reduces disease severity and prevents renal impairment in severe acute alcoholic hepatitis: a double blind, placebo controlled trial Abstract Hepatology 2006 44 (Suppl. 1 373A.
93. Macavoy NC, Forrest E, Hayes PC. The influence of Pentoxfylline on mortality in alcoholic hepatitis and benefit of the Glascow Alcoholic Hepatitis Score (GAHS) Abstract Hepatology 2005 42 (Suppl.1 492A.
94. Louvet A, Diaz E, Texier F, et al. Evaluation of Pentoxfylline in patients with severe alcoholic hepatitis non responders to corticosteroids: a pilot controlled study Abstract Hepatology 2005 42 (Suppl.1 493A.
95. Lebrec D, Thabut D, Oberti F, et al. Pentoxifylline for the treatment of patients with advanced cirrhosis. A randomized, placebo-controlled, double-blind trial Abstract Hepatology 2007 46 (Suppl. 1 249A.
96. McClain CJ, Song Z, Barve SS, Hill DB, Deaciuc I. Recent advances in alcoholic liver disease. IV. Dysregulated cytokine metabolism in alcoholic liver disease. Am J Physiol Gastrointest Liver Physiol 2004 287 : G497 502.
97. Spahr L, Rubbia-Brandt L, Frossard JL, et al. Combination of steroids with infliximab or placebo in severe alcoholic hepatitis: a randomized controlled pilot study. J Hepatol 2002 37 : 448 55.
98. Mookerjee RP, Sen S, Davies NA, Hodges SJ, Williams R, Jalan R. Tumour necrosis factor alpha is an important mediator of portal and systemic haemodynamic derangements in alcoholic hepatitis. Gut 2003 52 : 1182 7.
99. Tilg H, Jalan R, Kaser A, et al. Anti-tumor necrosis factor-alpha monoclonal antibody therapy in severe alcoholic hepatitis. J Hepatol 2003 38 : 419 25.
100. Naveau S, Chollet-Martin S, Dharancy S, et al. A double-blind randomized controlled trial of infliximab associated with prednisolone in acute alcoholic hepatitis. Hepatology 2004 39 : 1390 7.
101. Boetticher NC, Peine CJ, Kwo P, et al. A randomized, double-blinded, placebo-controlled multicenter trial of etanercept in the treatment of alcoholic hepatitis. Gastroenterology 2008 135 : 1953 60.
102. Brok J, Buckley N, Gluud C. Interventions for paracetamol (acetaminophen) overdose. Cochrane Database Syst Rev (Online) 2006 2 : CD003328.
103. Jones AL. Mechanism of action and value of N-acetylcysteine in the treatment of early and late acetaminophen poisoning: a critical review. J Toxicol Clin Toxicol 1998 36 : 277 85.
104. Israel Y, Orrego H. Propylthiouracil in the treatment of alcoholic liver disease. In : Lieber CS, ed. Biological Approach to Alcoholism. Washington, DC : Department of Health and Human Services, 1983 : 474 82.
105. Israel Y, Kalant H, Orrego H, Khanna JM, Videla L, Phillips JM. Experimental alcohol-induced hepatic necrosis: suppression by propylthiouracil. Proc Natl Acad Sci U S A 1975 72 : 1137 41.
106. Orrego H, Blake JE, Blendis LM, Compton KV, Israel Y. Long-term treatment of alcoholic liver disease with propylthiouracil. N Engl J Med 1987 317 : 1421 7.
107. Rambaldi A, Gluud C. Meta-analysis of propylthiouracil for alcoholic liver disease - a Cochrane Hepato-Biliary Group Review. Liver 2001 21 : 398 404. (Pubitemid 33095043)
108. Rambaldi A, Gluud C. Propylthiouracil for alcoholic liver disease. Cochrane Database Syst Rev (Online) 2005 4 : CD002800.
109. Rambaldi A, Gluud C. Anabolic-androgenic steroids for alcoholic liver disease. Cochrane Database Syst Rev (Online) 2006 4 : CD003045.
110. Rambaldi A, Jacobs BP, Iaquinto G, Gluud C. Milk thistle for alcoholic and/or hepatitis B or C liver diseases - a systematic cochrane hepato-biliary group review with meta-analyses of randomized clinical trials. Am J Gastroenterol 2005 100 : 2583 91.
111. Murray KF, Carithers RL. AASLD practice guidelines: evaluation of the patient for liver transplantation. Hepatology 2005 41 : 1 26.
112. Pfitzmann R, Schwenzer J, Rayes N, et al. Long-term survival and predictors of relapse after orthotopic liver transplantation for alcoholic liver disease. Liver Transpl 2007 13 : 197 205. (Pubitemid 46351644)
113. Bjornsson E, Olsson J, Rydell A, et al. Long-term follow-up of patients with alcoholic liver disease after liver transplantation in Sweden: impact of structured management on recidivism. Scand J Gastroenterol 2005 40 : 206 16.
114. DiMartini A, Day N, Dew MA, et al. Alcohol consumption patterns and predictors of use following liver transplantation for alcoholic liver disease. Liver Transpl 2006 12 : 813 20.
115. Pageaux GP, Bismuth M, Perney P, et al. Alcohol relapse after liver transplantation for alcoholic liver disease: does it matter? J Hepatol 2003 38 : 629 34.
116. Everhart JE, Beresford TP. Liver transplantation for alcoholic liver disease: a survey of transplantation programs in the United States. Liver Transpl Surg 1997 3 : 220 6.